Skadden represented Fresenius SE in the sale of Fresenius Biotech to the owners of Neopharm, Israel’s second-largest pharmaceutical company. The deal closed on June 28.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Skadden represented Fresenius SE in the sale of Fresenius Biotech to the owners of Neopharm, Israel’s second-largest pharmaceutical company. The deal closed on June 28.